Beijing Lu de Kai Qi Co., Ltd.

Chine

Retour au propriétaire
1-3 de 3 pour Beijing Lu de Kai Qi Co., Ltd. Trier par
Recheche Texte
Affiner par
Classe IPC
A61K 36/282 - Artemisia, p. ex. armoise 3
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat 3
A61K 36/52 - Juglandaceae (famille du noyer) 2
A61K 35/60 - Poissons, p. ex. hippocampesŒufs de poisson 1
A61K 36/258 - Panax (ginseng) 1
Voir plus
Résultats pour  brevets

1.

PHARMACEUTICAL PRODUCT FOR TREATING LUPUS ERYTHEMATOSUS AND COMBINED IMMUNE DEFECT, AND PREPARATION AND APPLICATION THEREOF

      
Numéro d'application CN2016078649
Numéro de publication 2017/173609
Statut Délivré - en vigueur
Date de dépôt 2016-04-07
Date de publication 2017-10-12
Propriétaire BEIJING LU DE KAI QI CO., LTD. (Chine)
Inventeur(s) Lu, Wei

Abrégé

A pharmaceutical product for treating lupus erythematosus and for enhancing immunity. The product comprises the following raw materials (in parts by weight): a Juglans regia extract (1), Blumea balsamifera extract (0.5-2), Panax quinquefolius extract (1-5), and Dendrobium nobile extract (1-10). The pharmaceutical product is prepared using a supercritical fluid extraction process and a spray drying process. The pharmaceutical product can enhance immunity and can prevent or treat lupus erythematosus.

Classes IPC  ?

2.

PHARMACEUTICAL PRODUCT FOR TREATING ANKYLOSING SPONDYLITIS AND COMBINED IMMUNE DEFECT, AND PREPARATION AND APPLICATION THEREOF

      
Numéro d'application CN2016078650
Numéro de publication 2017/173610
Statut Délivré - en vigueur
Date de dépôt 2016-04-07
Date de publication 2017-10-12
Propriétaire BEIJING LU DE KAI QI CO., LTD. (Chine)
Inventeur(s) Lu, Wei

Abrégé

A pharmaceutical product for treating ankylosing spondylitis and combined immune defect. Raw materials of the pharmaceutical product comprises a Rosa roxbunghii extract, a Blumea balsamifera extract, a seahorse extract, and a Corydalis yanhusuo extract respectively provided in a weight ratio of (1-10):(0.5-2):1:(1-10). The pharmaceutical product is prepared using a supercritical fluid extraction process, facilitating in vivo dissolution and human body absorption.

Classes IPC  ?

  • A61K 36/738 - Rosa (rose)
  • A61K 36/66 - Papaveraceae (famille du pavot), p. ex. sanguinaire du Canada
  • A61K 36/282 - Artemisia, p. ex. armoise
  • A61K 35/60 - Poissons, p. ex. hippocampesŒufs de poisson
  • A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
  • A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget
  • A61P 37/04 - Immunostimulants

3.

PHARMACEUTICAL PRODUCT FOR TREATING TUMOR AND COMBINED IMMUNE DEFECT, AND PREPARATION AND APPLICATION THEREOF

      
Numéro d'application CN2016078651
Numéro de publication 2017/173611
Statut Délivré - en vigueur
Date de dépôt 2016-04-07
Date de publication 2017-10-12
Propriétaire BEIJING LU DE KAI QI CO., LTD. (Chine)
Inventeur(s) Lu, Wei

Abrégé

A pharmaceutical composition for treating a tumor and combined immune defect. The composition comprises a Juglans regia extract, a Blumea balsamifera extract, and a Syzygium aromaticum extract provided in a weight ratio of 77:54:98. The composition can suppress microbial growth and exerts anti-microbial effects, enhance the immunity of an organism, provides stronger anticancer activity, and can prevent tumor recurrence. The composition is prepared using a supercritical fluid extraction process.

Classes IPC  ?

  • A61K 36/61 - Myrtaceae (famille du myrte), p. ex. cajeputier ou eucalyptus
  • A61K 36/52 - Juglandaceae (famille du noyer)
  • A61K 36/282 - Artemisia, p. ex. armoise
  • A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
  • A61P 35/00 - Agents anticancéreux